Administering an additional hepatitis B vaccination dose after 18 years maintains adequate long-term protection levels in healthcare workers
CONCLUSIONSWe confirm that seroprotection for vaccine-preventable disease is affected by treatment for pediatric malignancy. A single booster dose of vaccine might be a practical way to restore vaccine immunity in patients after chemotherapy.
ConclusionImmunoprophylaxis may need more consideration for HBsAb-positive patients receiving HBcAb-positive liver grafts. Active vaccination and mono-prophylaxis with NAs could be recommended in HBsAb-negative recipients against DNH. Further studies should examine the higher genetic barrier drugs for preventing DNH, and the association between DNH and HBV DNA-positive liver graft in this patient population.
Publication date: Available online 20 February 2020Source: Neurología (English Edition)Author(s): J.A. Crespo Burillo, Á. Gimenez Muñoz, J.M. Pérez Trullén
Publication date: Available online 17 February 2020Source: Antiviral ResearchAuthor(s): Yingying Dou, Diahann T.S.L. Jansen, Aniek van den Bosch, Robert A. de Man, Nadine van Montfoort, Can Araman, Sander I. van Kasteren, Gijs G. Zom, Willem-Jan Krebber, Cornelis J.M. Melief, Andrea M. Woltman, Sonja I. BuschowAbstractSynthetic long peptide (SLP) vaccination is a promising new treatment strategy for patients with a chronic hepatitis B virus (HBV) infection. We have previously shown that a prototype HBV-core protein derived SLP was capable of boosting CD4+ and CD8+ T cell responses in the presence of a TLR2-ligand in chroni...
Bone Marrow Transplantation, Published online: 18 February 2020; doi:10.1038/s41409-020-0833-5A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation
Abstract Synthetic long peptide (SLP) vaccination is a promising new treatment strategy for patients with a chronic hepatitis B virus (HBV) infection. We have previously shown that a prototype HBV-core protein derived SLP was capable of boosting CD4+ and CD8+ T cell responses in the presence of a TLR2-ligand in chronic HBV patients ex vivo. For optimal efficacy of a therapeutic vaccine in vivo, adjuvants can be conjugated to the SLP to ensure delivery of both the antigen and the co-stimulatory signal to the same antigen-presenting cell (APC). Dendritic cells (DCs) express the receptor for the adjuvant and are opti...
DISCUSSION: These results show the variation in the implementation of EU legislation in the participating countries. More consultation between actors at EU level, including enhancing medical surveillance in occupational medicine could help to optimise policies in European countries in order to further reduce HBV transmission to HCWs. PMID: 32057571 [PubMed - as supplied by publisher]
FRIDAY, Feb. 7, 2020 -- The hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP) adsorbed, inactivated poliovirus (IPV), Haemophilus influenza type b (Hib) conjugate (meningococcal protein conjugate), and hepatitis B...
This report summarizes the indications for DTaP-IPV-Hib-HepB and provides guidance for its use. PMID: 32027629 [PubMed - indexed for MEDLINE]
“Functional cure” is being pursued as the ultimate endpoint of antiviral treatment in chronic hepatitis B (CHB), which is characterized by loss of HBsAg whether or not anti-HBs antibodies are present. “Functional cure” can be achieved in